CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia.
Animals
Antibiotics, Antineoplastic
/ pharmacology
Apoptosis
/ drug effects
Calcitonin Gene-Related Peptide
/ metabolism
Calcitonin Receptor-Like Protein
/ antagonists & inhibitors
Cell Line, Tumor
Daunorubicin
/ pharmacology
Dipeptides
/ pharmacology
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cells
/ metabolism
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Mice
Mice, Inbred C57BL
Middle Aged
Neoplastic Stem Cells
/ metabolism
Piperazines
Quinazolines
/ pharmacology
Signal Transduction
AML
CALCRL
CGRP
chemotherapy resistance
leukemic stem cells
olcegepant
relapse
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
20 Nov 2019
20 Nov 2019
Historique:
received:
27
09
2019
revised:
15
11
2019
accepted:
18
11
2019
entrez:
24
11
2019
pubmed:
24
11
2019
medline:
14
4
2020
Statut:
epublish
Résumé
The neuropeptide CGRP, acting through the G-protein coupled receptor CALCRL and its coreceptor RAMP1, plays a key role in migraines, which has led to the clinical development of several inhibitory compounds. Recently, high
Identifiants
pubmed: 31756985
pii: ijms20235826
doi: 10.3390/ijms20235826
pmc: PMC6928760
pii:
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
CALCRL protein, human
0
Calcitonin Receptor-Like Protein
0
Dipeptides
0
Piperazines
0
Quinazolines
0
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
olcegepant
WOA5J8TX6M
Daunorubicin
ZS7284E0ZP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Austrian Science Fund FWF
ID : P 28013
Pays : Austria
Organisme : Austrian Science Fund
ID : P-28013
Organisme : Austrian Science Fund
ID : P-28256
Références
Blood. 2016 Jan 7;127(1):29-41
pubmed: 26660431
Nat Genet. 2013 Mar;45(3):290-4
pubmed: 23377183
J Mol Cell Cardiol. 2005 Dec;39(6):955-63
pubmed: 16242145
Immunity. 2007 Jun;26(6):726-40
pubmed: 17582345
Endocr Relat Cancer. 2010 Dec 13;18(1):C1-14
pubmed: 21051558
Haematologica. 2018 Mar;103(3):456-465
pubmed: 29242298
Blood. 2013 Feb 14;121(7):1077-82
pubmed: 23243288
Nature. 1998 May 28;393(6683):333-9
pubmed: 9620797
Blood. 2008 Aug 15;112(4):1366-73
pubmed: 18523155
Br J Haematol. 2000 Jan;108(1):140-50
pubmed: 10651737
Microsc Res Tech. 2002 Jul 15;58(2):85-90
pubmed: 12203707
Leuk Res Rep. 2016 Jun 16;6:1-7
pubmed: 27408788
Blood. 2008 Nov 15;112(10):4193-201
pubmed: 18716133
Exp Hematol. 2002 Apr;30(4):306-12
pubmed: 11937264
N Engl J Med. 2004 Apr 15;350(16):1617-28
pubmed: 15084694
Haematologica. 2005 Nov;90(11):1484-92
pubmed: 16266895
Oncogene. 2014 Jun 12;33(24):3091-8
pubmed: 23831573
Haematologica. 2009 Jan;94(1):131-4
pubmed: 18838472
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13550-5
pubmed: 18757746
Nat Med. 2011 Aug 28;17(9):1086-93
pubmed: 21873988
J Cell Physiol. 2010 Nov;225(3):701-8
pubmed: 20533307
Cephalalgia. 2011 Apr;31(6):748-50
pubmed: 21383046
Br J Cancer. 2015 Jan 20;112(2):329-37
pubmed: 25514379
Leukemia. 2009 Dec;23(12):2233-41
pubmed: 19727127
Leuk Lymphoma. 2015 Apr;56(4):1126-8
pubmed: 25030037
J Clin Pathol. 2006 Oct;59(10):1104-7
pubmed: 17021138
Cell Rep. 2013 Dec 26;5(6):1704-13
pubmed: 24332856
Sci Rep. 2019 Jun 24;9(1):9139
pubmed: 31235852
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Leukemia. 2019 Dec;33(12):2830-2841
pubmed: 31182782
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Headache. 2019 Jul;59 Suppl 2:20-32
pubmed: 31291020
Oncotarget. 2015 Nov 17;6(36):39098-110
pubmed: 26517675
Physiol Rev. 2014 Oct;94(4):1099-142
pubmed: 25287861
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leukemia. 2013 Apr;27(4):852-60
pubmed: 23235717
Hematology Am Soc Hematol Educ Program. 2012;2012:43-8
pubmed: 23233559
Hypertens Res. 2003 Feb;26 Suppl:S9-14
pubmed: 12630806
Int J Mol Sci. 2019 Apr 23;20(8):null
pubmed: 31018543
Hematology Am Soc Hematol Educ Program. 2008;:1-11
pubmed: 19074046
Leukemia. 2011 Dec;25(12):1825-33
pubmed: 21760593
Leuk Res. 2019 Sep;84:106180
pubmed: 31299413
Nature. 2006 Aug 17;442(7104):818-22
pubmed: 16862118
Cell Death Dis. 2019 Feb 11;10(2):116
pubmed: 30741933
Clin Exp Dermatol. 2007 Nov;32(6):650-3
pubmed: 17725664
Sci Rep. 2019 Jan 23;9(1):429
pubmed: 30674976
Neuroscience. 2002;113(1):155-66
pubmed: 12123694
J Hematol Oncol. 2017 Feb 20;10(1):51
pubmed: 28219393
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Carcinog. 2015 Dec;54(12):1815-9
pubmed: 25491945
Mol Cell Pharmacol. 2009;1(5):264-270
pubmed: 20336186
Genes Dev. 2011 Aug 1;25(15):1628-40
pubmed: 21828272
Drugs Aging. 2015 Dec;32(12):983-97
pubmed: 26446152
Nature. 2016 Dec 15;540(7633):433-437
pubmed: 27926740
Blood Adv. 2019 Apr 23;3(8):1330-1346
pubmed: 31015209
Arch Toxicol. 2017 May;91(5):2191-2208
pubmed: 27807597
Br J Haematol. 1997 Aug;98(2):399-407
pubmed: 9266939
Curr Opin Hematol. 2018 Mar;25(2):81-89
pubmed: 29278535
Contemp Oncol (Pozn). 2015;19(1A):A1-6
pubmed: 25691816
Nat Med. 2013 Mar;19(3):368-71
pubmed: 23377281
Cephalalgia. 2019 Dec;39(14):1827-1837
pubmed: 31288556
Nature. 2012 Jan 11;481(7382):506-10
pubmed: 22237025
Leukemia. 2013 Nov;27(11):2165-76
pubmed: 23628958